Nitrogen-containing tricyclic compounds acting as pyruvate dehydrogenase kinase 2 (PDHK2; PDK2) inhibitors have been described in a recent Japan Tobacco Inc. patent. They are reported to be useful for the treatment of diabetes, atherosclerosis, cancer, chronic kidney disease, Alzheimer’s disease, heart failure, pulmonary hypertension and stroke.